Thyas has signed an advisory agreement with Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy, Kyoto University Hospital (“KiCONNECT”; Sakyo-ku, Kyoto, Director Dr. Manabu Muto) for strategic planning for a clinical trial of autologous iPS cell-derived cytotoxic T cell therapy.